scholarly journals Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques

Virology ◽  
2007 ◽  
Vol 358 (1) ◽  
pp. 69-78 ◽  
Author(s):  
Flavia Ferrantelli ◽  
Kathleen A. Buckley ◽  
Robert A. Rasmussen ◽  
Alistair Chalmers ◽  
Tao Wang ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Time Dependence ◽  
Post Exposure Prophylaxis ◽  
Human Monoclonal Antibodies ◽  
Post Exposure ◽  
Exposure Prophylaxis

scholarly journals Development of broad‐spectrum human monoclonal antibodies for rabies post‐exposure prophylaxis

2016 ◽  
Vol 8 (4) ◽  
pp. 407-421 ◽  
Author(s):  
Paola De Benedictis ◽  
Andrea Minola ◽  
Elena Rota Nodari ◽  
Roberta Aiello ◽  
Barbara Zecchin ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Broad Spectrum ◽  
Post Exposure Prophylaxis ◽  
Human Monoclonal Antibodies ◽  
Post Exposure ◽  
Exposure Prophylaxis

Experimental utility of rabies virus-neutralizing human monoclonal antibodies in post-exposure prophylaxis

Vaccine ◽  
2001 ◽  
Vol 19 (28-29) ◽  
pp. 3834-3842 ◽  
Author(s):  
C.A Hanlon ◽  
C.A DeMattos ◽  
C.C DeMattos ◽  
M Niezgoda ◽  
D.C Hooper ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Rabies Virus ◽  
Post Exposure Prophylaxis ◽  
Human Monoclonal Antibodies ◽  
Post Exposure ◽  
Exposure Prophylaxis

Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques

AIDS ◽  
2003 ◽  
Vol 17 (3) ◽  
pp. 301-309 ◽  
Author(s):  
Flavia Ferrantelli ◽  
Regina Hofmann-Lehmann ◽  
Robert A Rasmussen ◽  
Tao Wang ◽  
Weidong Xu ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Post Exposure Prophylaxis ◽  
Human Monoclonal Antibodies ◽  
Post Exposure ◽  
Exposure Prophylaxis

scholarly journals Isolation and Characterization of Cross-Reactive Human Monoclonal Antibodies that Potently Neutralize Australian Bat Lyssavirus Variants and Other Phylogroup 1 Lyssaviruses

2021 ◽  
Author(s):  
Dawn Weir ◽  
Si'Ana Coggins ◽  
Bang Vu ◽  
Jessica Coertse ◽  
Lianying Yan ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
G Protein ◽  
Passive Immunization ◽  
Diagnostic Tools ◽  
Post Exposure Prophylaxis ◽  
Human Monoclonal Antibodies ◽  
Isolation And Characterization ◽  
Glycoprotein G ◽  
Exposure Prophylaxis ◽  
Australian Bat Lyssavirus

Australian bat lyssavirus (ABLV) is a rhabdovirus that circulates in four species of pteropid bats (ABLVp) and the yellow-bellied sheath-tailed bat (ABLVs) in mainland Australia. In the three confirmed human cases of ABLV, rabies illness preceded fatality. As with rabies virus (RABV), post-exposure prophylaxis (PEP) for potential ABLV infections consists of wound cleansing, ad-ministration of the rabies vaccine and injection of rabies immunoglobulin (RIG) proximal to the wound. Despite the efficacy of PEP, the inaccessibility of human RIG (HRIG) in the developing world and the high immunogenicity of equine RIG (ERIG) has led to consideration of human monoclonal antibodies (hmAbs) as a passive immunization option that offers enhanced safety and specificity. Using a recombinant vesicular stomatitis virus (rVSV) expressing the glycoprotein (G) protein of ABLVs and phage display, we identified two hmAbs, A6 and F11, which completely neutralize ABLVs/ABLVp, and RABV at concentrations ranging from 0.19-3.12 µg/mL and 0.39-6.25 µg/mL respectively. A6 and F11 recognize overlapping epitopes in the lyssavirus G protein, ef-fectively neutralizing phylogroup 1 lyssaviruses, while having little effect on phylogroup 2 and non-grouped diverse lyssaviruses. These results suggest A6 and F11 could be effective therapeutic and diagnostic tools for phylogroup 1 lyssavirus infections.

scholarly journals Health impact and cost of COVID-19 prophylaxis with monoclonal antibodies

2021 ◽  
Author(s):  
Abraham D. Flaxman ◽  
Rodal Issema ◽  
Ruanne V. Barnabas ◽  
Jennifer M. Ross
Keyword(s):  
United States ◽  
Monoclonal Antibodies ◽  
Health System ◽  
Vaccine Coverage ◽  
Unit Cost ◽  
The United States ◽  
Post Exposure Prophylaxis ◽  
Post Exposure ◽  
Exposure Prophylaxis ◽  
The Impact

Background: The COVID-19 pandemic has led to over 600,000 deaths in the United States and continues to disrupt lives even as effective vaccines are available. We aimed to estimate the impact and health system cost of implementing post-exposure prophylaxis against household exposure to COVID-19 with monoclonal antibodies. Methods: We developed a decision-analytical model analysis of results from a recent randomized controlled trial with complementary data on household demographic structure, vaccine coverage, and COVID-19 confirmed case counts for the representative month of May, 2021. The model population includes individuals of all ages in the United States by sex and race/ethnicity. Results: In a month of similar intensity to May, 2021, in the USA, a monoclonal antibody post-exposure prophylaxis program reaching 50% of exposed unvaccinated household members aged 50+, would avert 1,813 (1,171 - 2,456) symptomatic infections, 526 (343 - 716) hospitalizations, and 83 (56 - 116) deaths. Assuming the unit cost of administering the intervention was US$ 1,264, this program would save the health system US$ 3,055,202 (-14,034,632 - 18,787,692). Conclusions: Currently in the United States, health system and public health actors have an opportunity to improve health and reduce costs through COVID-19 post-exposure prophylaxis with monoclonal antibodies.

Recombinant monoclonal antibodies for rabies post-exposure prophylaxis

2018 ◽  
Vol 83 (1) ◽  
pp. 1-12 ◽  
Author(s):  
E. N. Ilina ◽  
M. V. Larina ◽  
T. K. Aliev ◽  
D. A. Dolgikh ◽  
M. P. Kirpichnikov
Keyword(s):  
Monoclonal Antibodies ◽  
Post Exposure Prophylaxis ◽  
Post Exposure ◽  
Exposure Prophylaxis
Sign in / Sign up

Export Citation Format

Share Document